Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by WCM Investment Management LLC

WCM Investment Management LLC trimmed its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 3.5% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 300,045 shares of the biopharmaceutical company’s stock after selling 10,784 shares during the period. WCM Investment Management LLC’s holdings in Halozyme Therapeutics were worth $17,094,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of HALO. TD Asset Management Inc lifted its holdings in Halozyme Therapeutics by 28.1% in the first quarter. TD Asset Management Inc now owns 2,541,266 shares of the biopharmaceutical company’s stock worth $103,379,000 after purchasing an additional 557,350 shares during the period. Boston Trust Walden Corp acquired a new stake in shares of Halozyme Therapeutics in the 2nd quarter worth approximately $23,211,000. CANADA LIFE ASSURANCE Co boosted its holdings in shares of Halozyme Therapeutics by 29.5% in the first quarter. CANADA LIFE ASSURANCE Co now owns 130,856 shares of the biopharmaceutical company’s stock valued at $5,321,000 after acquiring an additional 29,845 shares in the last quarter. Swedbank AB acquired a new position in shares of Halozyme Therapeutics during the first quarter valued at approximately $13,927,000. Finally, Mizuho Markets Americas LLC raised its holdings in Halozyme Therapeutics by 2.2% during the first quarter. Mizuho Markets Americas LLC now owns 456,636 shares of the biopharmaceutical company’s stock worth $18,576,000 after purchasing an additional 9,975 shares in the last quarter. Institutional investors own 97.79% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on HALO. HC Wainwright increased their price target on Halozyme Therapeutics from $65.00 to $68.00 and gave the company a “buy” rating in a research note on Friday, November 1st. TD Cowen lifted their target price on Halozyme Therapeutics from $59.00 to $65.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. The Goldman Sachs Group boosted their price target on shares of Halozyme Therapeutics from $44.00 to $49.00 and gave the stock a “neutral” rating in a research report on Monday, July 22nd. JPMorgan Chase & Co. cut shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their price objective for the stock from $52.00 to $57.00 in a research note on Thursday, September 19th. Finally, Piper Sandler boosted their target price on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a report on Monday, November 4th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $61.11.

Insider Buying and Selling at Halozyme Therapeutics

In other news, Director Matthew L. Posard sold 9,881 shares of the firm’s stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $57.70, for a total value of $570,133.70. Following the completion of the sale, the director now owns 69,874 shares of the company’s stock, valued at $4,031,729.80. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. In related news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $61.75, for a total transaction of $617,500.00. Following the transaction, the senior vice president now directly owns 168,176 shares of the company’s stock, valued at approximately $10,384,868. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Matthew L. Posard sold 9,881 shares of the stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $57.70, for a total transaction of $570,133.70. Following the completion of the sale, the director now owns 69,874 shares of the company’s stock, valued at approximately $4,031,729.80. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 79,881 shares of company stock valued at $4,612,634 in the last three months. 2.40% of the stock is currently owned by company insiders.

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics stock opened at $61.09 on Tuesday. The firm’s 50 day simple moving average is $56.56 and its 200-day simple moving average is $53.03. Halozyme Therapeutics, Inc. has a fifty-two week low of $33.15 and a fifty-two week high of $65.53. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. The company has a market cap of $7.77 billion, a P/E ratio of 20.23, a price-to-earnings-growth ratio of 0.56 and a beta of 1.29.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.